(43 days)
Not Found
No
The device description details a standard enzyme immunoassay (ELISA) kit based on chemical reactions and optical density measurements, with no mention of AI or ML algorithms for data analysis or interpretation.
No
This device is an in-vitro diagnostic test kit designed to measure FSH levels for diagnostic purposes, not to treat any medical condition.
Yes
The intended use states that "Measurements of follicle-stimulating hormone are used in the diagnosis of pituitary gland and gonadotropin disorders," indicating its use in diagnosing medical conditions.
No
The device description clearly outlines a physical ELISA kit with reagents and a microplate, indicating it is a hardware-based diagnostic test, not software only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is the "quantitative determination of follicle stimulating hormone (FSH) concentration in human serum and plasma." This clearly indicates that the device is used to test samples taken from the human body (in vitro) to provide diagnostic information.
- Indications for Use: The measurements are used "in the diagnosis of pituitary gland and gonadotropin disorders." This further confirms the diagnostic purpose of the device.
- Device Description: The description details an "enzymeimmunoassay (ELISA) kit" for determining FSH in human serum and plasma. ELISA is a common in vitro diagnostic technique.
- Sample Type: The device uses "human serum and plasma," which are biological specimens taken from the body.
All of these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The quantitative determination of follicle stimulating hormone (FSH) concentration in human serum and plasma by a microplate enzymeimmunoassay. Measurements of follicle-stimulating hormone are used in the diagnosis of pituitary gland and gonadotropin disorders.
Product codes
CGJ
Device Description
The Monobind ELISA method is based on two-site immunoassay (sandwich) technology utilizing the streptavidin-blotin reaction to effect separation. Upon mixing monoclonal blotinylated anti-FSH antibody, the enzyme-labeled anti-FSH antibody and a serum containing the native antigen (FSH), reaction results between the natlve antigen (FSH) and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. After incubation is complete, decantation or aspiration separates the bound fraction. The enzyme activity on the well Is directly proportional to the native antigen (FSH) concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Substantial equivalency was based on clinical comparison (linear regression), using 128 specimens from low to elevated populations. The values ranged from 0.1 - 133 mlU/ml.The mean values for reference method (ICMA) and this method (microplate ELISA) are 21.0 mlU/ml and 18.0 mlU/ml respectively. The equation to a straight-line [y= 0.93 (x) - 1.5 ) and correlation coefficient (0.994) indicates good method agreement.
In addition recovery data demonstrated an average recovery of 99.9% when exogenous added follicle-stimulating hormone was introduced into human serum specimens. Similarly, linearity studies showed an average 93.8% when specimens were diluted and compared to the dose response curve.
Key Metrics
Equation to a straight-line [y= 0.93 (x) - 1.5 ), correlation coefficient (0.994), average recovery of 99.9%, average linearity of 93.8%.
Predicate Device(s)
K972720, Ciba Corning ACS 180 chemiluminescence (ICMA) test
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1300 Follicle-stimulating hormone test system.
(a)
Identification. A follicle-stimulating hormone test system is a device intended to measure follicle-stimulating hormone (FSH) in plasma, serum, and urine. FSH measurements are used in the diagnosis and treatment of pituitary gland and gonadal disorders.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
K 4"1A 120
Image /page/0/Picture/1 description: The image shows a logo for MONOBIND, INC. The logo features a stylized, interconnected design that resembles the letters 'M' and 'B'. Below the logo, the text "MONOBIND, INC." is printed in a bold, sans-serif font. The date "Jul. 11, 97" is printed below the company name.
SEP - 2 1997
510(k) Summarv
Dear Sir:
Monobind Inc., registration number 2020726, plans to introduce Into commercial distribution an enzymeimmunoassay (ELISA) kit for the determination of folliclestimulating hormone (FSH) in human serum and plasma.
The proprietary name is Follicle-stimulating hormone (FSH) ELISA and the usual name is FSH ELISA. This device classification name is - follicle-stimulating hormone test system product code CGJ (per 21 CRF section 862.1300).
This device is substantially equivalent to the Ciba Corning ACS 180 chemiluminescence (ICMA) test, which predicates the new device.
The contact individual for this submission is Dr. Frederick R. Jerome.
The Monobind ELISA method is based on two-site immunoassay (sandwich) technology utilizing the streptavidin-blotin reaction to effect separation. Upon mixing monoclonal blotinylated anti-FSH antibody, the enzyme-labeled anti-FSH antibody and a serum containing the native antigen (FSH), reaction results between the native antigen (FSH) and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. After incubation is complete, decantation or aspiration separates the bound fraction. The enzyme activity on the well Is directly proportional to the native antigen (FSH) concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.
The Intended use of the device: The quantitative determination of follicle-stimulating hormone (FSH) concentration in human serum and plasma by a microplate enzymelmmunoassay. Measurements of FSH are used in the diagnosis of pituitary gland and gonadotropin disorders.
The technological characteristics of the new device compared to the predicate device are very similar. This includes the use of two-site immunoassay (sandwich) technology using monoclonal and polyclonal antibodies, and human serum prepared callbrators (standardized against the same international reference material). The main difference resides in the use of an enzyme tracer compared to chemiluminescence as well as magnetic particles versus streptavidin coated polystyrene wells.
Substantial equivalency was based on clinical comparison (linear regression), using 128 specimens from low to elevated populations. The values ranged from 0.1 - 133 mlU/ml.The mean values for reference method (ICMA) and this method (microplate ELISA) are 21.0 mlU/ml and 18.0 mlU/ml respectively. The equation to a straight-line [y= 0.93 (x) - 1.5 ) and correlation coefficient (0.994) indicates good method agreement.
In addition recovery data demonstrated an average recovery of 99.9% when exogenous added follicle-stimulating hormone was introduced into human serum specimens. Similarly, linearity studies showed an average 93.8% when specimens were diluted and compared to the dose response curve.
729 West 16" Street , Costa Mesa , CA (USA) 92627 Phone: (714) 642-4830 FAX: (714) 650-8459
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Dr. Frederick R. Jerome . Monobind, Inc. 729 West 16th Street 92627 Costa Mesa, California
SEP - 2 1997
Re : K972720 Follicle Stimulating Hormone (FSH) ELISA Requlatory Class: I Product Code: CGJ Dated: July 14, 1997 Received: July 21, 1997
Dear Dr. Jerome:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical General requlation (21 CFR Part 320) and that, Devices: through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
:
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
sincerely yours,
Steven Ditman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Indications for Use Statement
510(k) Number (if known):
:中国商城 中国旅游客
,可能
新闻网
Device Name: Follicle Stimulating Hormone (FSH) Microplate EIA
The quantitative determination of follicle stimulating hormone (FSH) concentration in human serum and plasma by a microplate enzymeimmunoassay.Measurements of follicle-stimulating hormone are used in the diagnosis of pituitary gland and gonadotropin disorders.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K972720 |
| Prescription Use | OR | Over-The-Counter Use | ||
|---|---|---|---|---|
| (Per 21 CFR 801.109) | (Optional Folmat 1-2-96) |